Effects of the levonorgestrel-releasing intrauterine system versus the copper intrauterine device on uterine artery Doppler indices.

What Was Tested

Researchers studied Copper (Supplement) in this randomized controlled trial publication.

The aims of the study were to evaluate the effects of two types of intrauterine contraceptive device (IUCD) on uterine artery Doppler indices.

Who Took Part

The abstract describes 33 participants taking part.

PubMed indexes the participants as teenagers, young adults, adults and middle-aged adults, women only.

Sixty-six multiparous women aged 18-45 years seeking intrauterine contraception were randomly assigned to receive either the levonorgestrel-releasing intrauterine system (LNG-IUS) or the copper intrauterine device (Cu-IUD).

Each group comprised 33 participants.

How the Study Was Run

The design is described as randomized and multicenter.

Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Running at several centres spread the Copper (Supplement) study over different clinics and patient groups.

A multicentre randomised clinical trial was conducted between November 2019 and August 2020.

Primary outcome measures were menstrual changes and changes in uterine artery Doppler indices 3 and 6 months after IUCD insertion.

Secondary outcomes measures were the relation between Doppler indices and menstrual changes, adverse effects of the assigned contraceptive method and user acceptability of the method.

What Was Measured

Topics PubMed links to this paper include Contraceptive Agents, Female, Intrauterine Devices, Copper, Intrauterine Devices, Medicated, Levonorgestrel, Ultrasonography, Doppler and Uterine Artery.

The authors tagged it with the keywords Intrauterine contraceptive devices and uterine artery Doppler ultrasound.

What This Means in Plain Language

The paper is a randomized and multicenter study of Copper (Supplement) in 33 participants.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2022 (The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception), a journal based in England.

More context: the Copper (Supplement) compound page, all human trials.